Marshall Schorin, MD

Undergraduate - Massachusetts Institute of Technology (1971)
Medical School - University of Pennsylvania School of Medicine (1975)
Residency - University of Rochester/Strong Memorial Hospital (1980)
Fellowship - Children’s Hospital Boston/Sidney Farber Cancer Institute/Harvard Medical School (1983)

Top Doctors Recognition - Northern Virginia Magazine 

Schorin MA, Blattner S, Gelber RD, Tarbell NJ, Donnelly M, Dalton V, Cohen HJ, Sallan SE. Treatment of childhood acute lymphoblastic leukemia: results of Dana-Farber Cancer Institute/Children's Hospital ALL consortium protocol 85-01. J Clin Oncol 1994; 12:740-7.

Lipshultz SE, Rifai N, Dalton VM, Levy DE, Silverman LB, Lipsitz SR, Colan SD, Asselin BA, Barr RD, Clavell LA, Hurwitz CA, Moghrabi A, Samson Y, Schorin MA, Gelber RD, Sallan SE. Dexrazoxane reduces myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia. N Engl J Med 2004 July 8; 351(2):145-53.

Janson K, Nedzi LA, David O, Schorin M, Walsh JW, Bhattacharjee M, Pridjian G, Tan L, Judkins AR, Biegel JA. Predisposition to atypical teratoid/rhabdoid tumor due to an inherited INI1 mutation. Pediatr Blood Cancer 2006; 47:279-84.

Lipshultz SE, Scully RE, Lipsitz SR, Sallan SE, Silverman LB, Miller TL, Barry EV, Asselin BL, Athale U, Clavell LA, Larsen E, Moghrabi A, Samson Y, Michon B, Schorin MA, Cohen HJ, Neuberg DS, Orav EJ, Colan SD. Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial. Lancet Oncol 2010; 11:950-61.

Vrooman LM, Stevenson KE, Supko JG, O’Brien J, Dahlberg S, Asselin BL, Athale UH, Clavell L, Kelly KM, Kutok JL, Laverdière C, Lipshultz SE, Michon B, Schorin M, Relling MV, Cohen HJ, Neuberg DS, Sallan SE, Silverman LB. Post-induction dexamethasone and individualized dosing of E. coli l-asparaginase each improve outcome of children and adolescents with newly diagnosed acute lymphoblastic leukemia: results from a randomized study, Dana-Farber Cancer Institute ALL Consortium protocol 00-01. J Clin Oncol. 2013 Jan 28.